Loading stock data…
VOR
$13.85-0.48 (-3.35%)
Market ClosedLast close May 1
Vor Biopharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vor Biopharma Inc. in the Healthcare sector is trading at $13.85. The stock is currently near its 52-week low of $2.62, remaining 38.3% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why VOR maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.85
Potential Upside
5%
Whystock Fair Value$14.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$37.50+170.8%
Range$15.00 – $50.00
Fundamentals
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$708.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.92
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
423.57%
Volume
Today's trading volume
543,979
Recent News
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate telitacicept. JPMorgan’s initiation of coverage, citing telitacicept as highly de-risked across multiple indications, underscores how external validation is shaping investor perception of Vor’s pipeline. With the shares rising meaningfully over the past week, we’ll examine how telitacicept’s Phase 3...
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term commercial opportunity. See our latest analysis for Vor Biopharma. Those telitacicept headlines have clearly reset expectations, with a 1 day share price return of 28.23 percent and a 7 day share price return of 25.97 percent at 10.72 dollars. However, the 1 year total shareholder return is still down...